Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allakos Inc.
  6. Summary
    ALLK   US01671P1003

ALLAKOS INC.

(ALLK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
78.35(c) 79.6(c) 76.39(c) 74.02(c) 70.75(c) Last
410 828 618 651 583 860 513 779 747 033 Volume
-0.82% +1.60% -4.03% -3.10% -4.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -241 M - -
Net cash position 2021 483 M - -
P/E ratio 2021 -15,9x
Yield 2021 -
Sales 2022 5,49 M - -
Net income 2022 -315 M - -
Net cash position 2022 430 M - -
P/E ratio 2022 -12,8x
Yield 2022 -
Capitalization 3 843 M 3 843 M -
EV / Sales 2021 -
EV / Sales 2022 622x
Nbr of Employees 167
Free-Float 93,6%
More Financials
Company
Allakos Inc. is a clinical stage biopharmaceutical company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory and proliferative diseases. Its initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis, inflammatory diseases of the gastrointestinal tract. The Company is focused on... 
More about the company
Ratings of Allakos Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ALLAKOS INC.
11/30Allakos Expands Development of Lirentelimab Into Dermatitis, Hives, Asthma
MT
11/30ALLAKOS : Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic ..
PU
11/30ALLAKOS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/30Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic..
AQ
11/30Allakos Inc. Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Ch..
CI
11/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
11/10Morgan Stanley Adjusts Price Target on Allakos to $86 From $88, Maintains Equal-Weight ..
MT
11/08Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results - For..
PU
11/08ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/08Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
GL
11/08Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
10/25ALLAKOS : Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Dise..
PU
10/25ALLAKOS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/25ALLAKOS : Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates o..
AQ
10/24ALLAKOS : Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Dise..
AQ
More news
News in other languages on ALLAKOS INC.
06/07Allakos achève le recrutement de patients dans deux études évaluant le lirentelimab ; l..
05/11La perte d'Allakos au premier trimestre se creuse
03/31Un initié d'Allakos (ALLK) réalise une importante vente d'actions
03/25Les ventes importantes d'initiés sur les actions d'Allakos (ALLK) se poursuivent
03/17Un initié d'Allakos (ALLK) réalise une importante vente d'actions
More news
Analyst Recommendations on ALLAKOS INC.
More recommendations
Chart ALLAKOS INC.
Duration : Period :
Allakos Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLAKOS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 70,75 $
Average target price 142,90 $
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Robert Alexander Chief Executive Officer & Director
Adam L. Tomasi President & Chief Operating Officer
Harlan Baird Radford Chief Financial Officer
Daniel S. Janney Chairman
Ruby Casareno Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALLAKOS INC.-49.46%3 843
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.78%63 017
VERTEX PHARMACEUTICALS-13.24%52 137